FrancophonIA/ELRC3.0 huggingface dataset:
English: The second study involved adults whose uveitis was under control with a corticosteroid but the corticosteroid dose was then reduced or stopped and Humira or placebo introduced.
Estonian: Teises uuringus osalesid täiskasvanud patsiendid, kelle uveiit allus ravile kortikosteroidiga, kuid kortikosteroidi annust seejärel vähendati või ravi katkestati ja selle asemel alustati Humira või platseebo kasutamist.
English: The most common side effects with Humira (which may affect more than 1 in 10 people) are infections (including in the nose, throat and sinuses), injection site reactions (redness, itching, bleeding, pain or swelling), headache and muscle and bone pain.
Estonian: Humira kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on infektsioonid (sh nina-neelu- ja nina kõrvalurgete infektsioonid), süstekoha reaktsioonid (punetus, sügelus, verejooks, valu või turse), peavalu ning lihase- ja luuvalu.
English: The studies included adult patients for the most part, but included children in studies for Crohn's disease, plaque psoriasis, polyarticular juvenile idiopathic arthritis, non-infectious anterior uveitis and enthesitis-related arthritis.
Estonian: Enamikes uuringutes osalesid täiskasvanud patsiendid, kuid lapsed osalesid Crohni tõve, naastulise psoriaasi, lapseea idiopaatilise polüartriidi, mittenakkusliku anterioorse uveiidi ja entesiidiga seotud artriidi uuringutes.
English: Other rare serious side effects (which may affect up to 1 in 1,000 people) include failure of bone marrow to produce blood cells, disorder of the nerves, lupus and lupus-like conditions (where the immune system attacks the patient's own tissues, causing inflammation and organ damage), and Stevens-Johnson syndrome (a life-threatening reaction with flu-like symptoms and painful rash affecting the skin, mouth, eyes and genitals).
Estonian: Muud harvad rasked kõrvalnähud (võivad esineda kuni 1 patsiendil 1000st) on muu hulgas luuüdi suutmatus toota vererakke, närvihäired, luupus ja luupuselaadne seisund (immuunsüsteem ründab patsiendi enda kudesid, mis põhjustab põletikku ja kahjustab organeid) ja Stevensi-Johnsoni sündroom (eluohtlik reaktsioon gripilaadsete sümptomitega ning nahal, suus, silmadel ja suguelunditel esineva valuliku lööbega).
English: For more information about using Humira, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Humira kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: This substance is involved in causing inflammation and is found at high levels in patients with the diseases that Humira is used to treat.
Estonian: See aine osaleb põletiku tekitamisel ning selle sisaldus on suur patsientidel, kelle haigusi ravitakse Humiraga.
English: Humira contains the active substance adalimumab.
Estonian: Humira sisaldab toimeainena adalimumaabi.
English: Fewer patients receiving Humira with methotrexate developed antibodies against Humira (which can reduce its effects), so the results found that the use of Humira with methotrexate was more effective than Humira used alone.
Estonian: Vähe oli Humirat koos metotreksaadiga kasutanud patsiente, kellel tekkisid Humira vastu antikehad (mis võivad selle mõju vähendada), ning uuringu tulemused toetavad pigem Humira kasutamist koos metotreksaadiga kui ainsa ravimina.
English: An overview of Humira and why it is authorised in the EU
Estonian: Ülevaade ravimist Humira ja ELis müügiloa väljastamise põhjendus
English: Humira, when used as directed, has been shown in clinical trials to be effective at reducing important symptoms of each of the conditions for which it is approved.
Estonian: Kliinilistes uuringutes osutus Humira õige kasutamise korral efektiivseks kõikide seisundite oluliste sümptomite vähendamisel, mille raviks on Humira heaks kiidetud.
English: Humira has been studied extensively and has been shown to be effective at reducing symptoms in patients with inflammatory conditions.
Estonian: Humira osutus põhjalikes uuringutes efektiivseks patsientide põletikuliste seisundite sümptomite vähendamisel.
English: What benefits of Humira have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Humira kasulikkus?
English: • axial spondyloarthritis (inflammation of spine causing back pain), including ankylosing spondylitis and when X-ray does not show disease but there are clear signs of inflammation
Estonian: • aksiaalne spondüloartriit (seljavalu põhjustav lülisambapõletik), sealhulgas jäigastav spondüliit, kui röntgeniuuring ei näita haiguskahjustusi, kuid on selged põletikunähud;
English: In the third study in children aged 2 to 18 years with non-infectious anterior uveitis, in whom methotrexate alone did not work, treatment failed in about 60% of patients receiving placebo with methotrexate compared with about 27% of patients given Humira with methotrexate.
Estonian: Kolmandas uuringus, milles osalesid 218-aastased mittenakkusliku anterioorse uveiidiga lapsed, kellel metotreksaadi kasutamine ainsa ravimina ei olnud õnnestunud, ebaõnnestus ravi platseebot koos metotreksaadiga kasutanud patsientidest ligikaudu 60% ja Humirat koos metotreksaadiga kasutanud patsientidest ligikaudu
English: For detailed information on the use of Humira in all conditions, including when it can be used in children, see package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Humira kasutamise kohta kõigi nende seisundite raviks, sealhulgas lastel, vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: • In rheumatoid arthritis, the greatest reductions in symptoms were seen in the studies on Humira as an add-on to methotrexate: around two-thirds of the patients adding Humira had at least a 20% reduction in symptoms after six months, compared with a quarter of those adding placebo.
Estonian: • Reumatoidartriidi sümptomid vähenesid kõige rohkem uuringutes, milles Humirat kasutati lisaks metotreksaadile: kuue kuu pärast vähenesid sümptomid Humira lisamisel vähemalt 20% võrra ligikaudu kahel kolmandikul patsientidest ja platseebo lisamisel veerandil.
English: The dose and frequency of injection depends on the condition to be treated and the dose for a child is calculated according to the child's weight.
Estonian: Ravimi annus ja manustamissagedus sõltuvad ravitavast seisundist.
English: For the full list of restrictions with Humira, see the package leaflet.
Estonian: Humira kohta teatatud piirangute täielik loetelu on pakendi infolehel.
English: • In studies in adults and children with plaque psoriasis, including psoriasis of the nail, a higher proportion of patients receiving Humira had improvements in symptoms compared with patients receiving methotrexate or placebo (a dummy treatment).
Estonian: • Naastulise psoriaasiga, sealhulgas küünepsoriaasiga täiskasvanute ja laste uuring tõendas, et Humirat kasutanud patsientidel leevenesid sümptomid rohkem kui metotreksaati või platseebot (näiv ravim) kasutanud patsientidel.
English: In this study treatment failed in about 79% of patients receiving placebo compared with about 55% given Humira.
Estonian: Selles uuringus oli patsiente, kelle ravi ebaõnnestus, platseeborühmas ligikaudu 79% ja Humira rühmas ligikaudu 55%.
English: In this study, treatment failure occurred in about 55% of patients receiving placebo compared with 39% receiving Humira.
Estonian: Selles uuringus oli patsiente, kelle ravi ebaõnnestus, platseeborühmas ligikaudu 55% ja Humira rühmas 39%.
English: More than twenty main studies involving over 9,500 patients have looked at the effects of Humira in reducing symptoms of inflammatory conditions.
Estonian: Humira mõju põletikuliste seisundite sümptomite vähendamisel vaadeldi enam kui 20 põhiuuringus, milles osales rohkem kui 9500 patsienti.
English: Humira can only be obtained with a prescription.
Estonian: Humira on retseptiravim.
English: Doctors treating uveitis should also take advice from doctors who have experience of using Humira.
Estonian: Uveiiti ravivad arstid peavad konsulteerima Humira kasutamise kogemusega spetsialistiga.
English: • In hidradenitis suppurativa, 59% of patients receiving Humira in one main study and 42% of patients in another achieved at least a 50% reduction in abscesses and nodules after 12 weeks, without any increase in abscess count or fistulas.
Estonian: • Hidradeniidi korral oli 12 ravinädala järel patsiente, kellel vähenesid abstsessid ja sõlmed vähemalt 50%, ilma et abstsesside või fistulite arv oleks suurenenud, ühes põhiuuringus Humira rühmas 59% ja teises uuringus 42%.
English: For the full list of side effects of Humira, see the package leaflet.
Estonian: Humira kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: • In polyarticular juvenile idiopathic arthritis, around 40% of patients aged between 4 and 17 years receiving Humira, either alone or in combination with methotrexate, had a flare-up of arthritis, compared with around 69% of those receiving placebo.
Estonian: • Lapseea idiopaatilise polüartriidi ravis oli 4-17-aastastest patsientidest neid, kellel haigus ägenes, Humirat ainsa ravimina või koos metotreksaadiga kasutanud patsiendirühmas ligikaudu 40% ja platseeborühmas ligikaudu 69%.
English: Humira must not be used in patients with active tuberculosis or other severe infections, or in patients with moderate to severe heart failure (an inability of the heart to pump enough blood around the body).
Estonian: Humirat ei tohi kasutada aktiivse tuberkuloosi, muu raske infektsiooni ja mõõduka kuni raske südamepuudulikkusega patsiendid.
English: • psoriatic arthritis (red, scaly patches on the skin with inflammation of the joints)
Estonian: • psoriaatiline artriit (punased ketendavad nahalaigud koos liigesepõletikuga);
English: For enthesitis-related arthritis, treatment with Humira resulted in fewer swollen and tender joints compared with placebo.
Estonian: Entesiidiga seotud artriidi ravis vähenes tursunud ja tundlike liigeste arv Humira kasutamisel rohkem kui platseeboga.
English: Treatment with Humira must be started and supervised by a doctor who has experience in the treatment of the diseases that Humira is used for.
Estonian: Ravi Humiraga tohib alustada üksnes Humiraga ravitavate haiguste ravis kogenud arst ning ravi peab toimuma tema järelevalve all.
English: • Humira also produced a greater improvement in symptoms than placebo in studies of psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis without evidence in the X-ray of ankylosing spondylitis but with clear signs of inflammation, and induction and maintenance phases of treatment for Crohn's disease, psoriasis and ulcerative colitis.
Estonian: • Psoriaatilise artriidi, jäigastava spondüliidi, spondüolartriidi (kui röntgenuuring ei kinnitanud jäigastavat spondüliiti, kuid olid selged põletikunähud) ning Crohni tõve induktsioon- ja säilitusravi, psoriaasi ja haavandilise koliidi korral paranesid Humira kasutamisel sümptomid rohkem kui platseebo kasutamisel.
English: • plaque psoriasis, a disease causing red, scaly patches on the skin
Estonian: • naastuline psoriaas (haigus, mis põhjustab punaseid ketendavaid laike nahal);
English: Why is Humira authorised in the EU?
Estonian: ELis Humirale väljastatud müügiloa põhjendus
English: • ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut)
Estonian: • haavandiline koliit (soole limaskesta põletikku ja haavandeid tekitav haigus);
English: 3641 RT Mijdrecht The Netherlands
Estonian: 3641 RT Mijdrecht Holland
English: 1103 Budapest, Hungary
Estonian: 1103 Budapest Ungari
English: D-13353 Berlin postal address:
Estonian: 13353 Berlin postiaadress:
English: Mommaertslaan B- 1831 Diegem
Estonian: Mommaertslaan B- 1831 Diegem Belgia
English: UK - United Kingdom
Estonian: UK - Ühendkuningriik
English: 555,6 Ph.Eur.u.
Estonian: 555,6 j. Ph.Eur.
English: Gedeon Richter Ltd. Gyomroi ut 19-21 Budapest HU-1103 Hungary
Estonian: Gedeon Richter Ltd. Gyomroi ut 19-21 Budapest HU-1103 Ungari
English: 1111,1 Ph.Eur.u.
Estonian: 1111,1 j. Ph.Eur.
English: BAYER SANTE - 220, avenue de la recherche - 59120 LOOS
Estonian: FR- Prantsusmaa BAYER SANTE 220, avenue de la recherche 59120 LOOS
English: 51368 Leverkusen, Germany
Estonian: 51368 Leverkusen Saksamaa
English: Aprotinin containing medicinal products with Marketing Authorisation in the European Union
Estonian: Euroopa Liidus müügiluba omavad aprotiniini sisaldavad ravimid EL/EMP
English: Trasylol 10.000 KIE/mlInfusionsflasche
Estonian: 10.000 KIE/mlInfusionsflasche
English: BE-Belgium Belgium Bayer S.A. 14, J.E.
Estonian: Belgium Bayer S.A. 14, J.E.
English: Nordic Pharma Limited, Abbey House, 1650 Arlington Business Park, Theale, Reading, Berkshire RG7 4SA, UK
Estonian: 1650 Arlington Business Park Theale, Reading Berkshire RG7 4SA Ühend-kuningriik
English: Quinta do Pinheiro 5 2794-003 Carnaxide Portugal
Estonian: Bayer Portugal, S.A. Rua Quinta do Pinheiro 5 2794-003 Carnaxide Portugal
English: LU - Luxembourg Bayer S.A. 14, J.E.
Estonian: LU-Luksemburg Bayer S.A. 14, J.E.
English: Bayer Pharma Aktiengesellschaft registered business address: Müllerstr.
Estonian: Bayer Pharma Aktiengesellschaft Registreeritud tegevuskoha aadress: Müllerstr.
English: Bayer Vital GmbH D-51373 Leverkusen
Estonian: DE- Saksamaa Bayer Vital GmbH 51368 Leverkusen
English: EL - Greece
Estonian: EL-Kreeka
English: PL - Poland
Estonian: PL- Poola
English: DK - Denmark
Estonian: DK-Taani
English: Bayer Pharma AG Berlin, D-13342, Germany
Estonian: Bayer Pharma AG 13342 Berlin Saksamaa
English: Belgium
Estonian: BE-Belgia
English: Bayer Hellas AG 18 - 20 , Sorou Str.
Estonian: Bayer Hellas AG 18 - 20 , Sorou Str. 151 25 , Marousi Athens
English: SL - Slovenia
Estonian: SI-Sloveenia
English: Bayer Schering Pharma AG, Müllerstrasse 170-178, DE13342 Berlin, Germany
Estonian: Bayer Schering Pharma AG Müllerstrasse 170-178 13353 Berlin
English: 500 000 UIK/50 mL
Estonian: 500 000 UIK / 50 mL Süstelahus
English: ES - Spain
Estonian: ES-Hispaania
English: Bayer HealthCare AG, 51368 Leverkusen, Germany solution for injection/infusion intravenous use
Estonian: Bayer HealthCare AG 51368 Leverkusen Saksamaa
English: Pharmaceutical form
Estonian: Perfusioonilahus
English: 2000000 U.I.C/200 ml
Estonian: 2000000 U.I.C / 200 ml Infusioonilahus
English: Germany
Estonian: Kreeka
English: H-1475 Hungary
Estonian: Pf. 27., H-1475
English: Bayer d.o.o., Bravničarjeva 13, Ljubljana, Slovenia solution for injection and infusion intravenous use
Estonian: Bravničarjeva 13 Ljubljana Sloveenia
English: Bayer House Strawberry Hill Newbury
Estonian: Strawberry Hill
English: Richter Gedeon Nyrt., Budapest Pf. 27.,
Estonian: SK - Slovakkia Richter Gedeon Nyrt Budapest 10
English: 1000000 U.I.C/100 ml
Estonian: 1000000 U.I.C / 100 ml Infusioonilahus
English: Route of administration
Estonian: Energieweg 1
English: Av. Baix Llobregat, 3-5 08970 Sant Joan Despi Barcelona - España
Estonian: Sant Joan Despi 08970
English: FI - Finland
Estonian: FI-Soome
English: Berkshire RG14 1JA United Kingdom trading as Bayer Plc, Pharmaceutical division
Estonian: Turustaja: Bayer Plc, Pharmaceutical Division
English: Trasylol 500 000 KIE
Estonian: Trasylol 500 000 KIE 10 ku/ml
English: 10.000 K10.000 KIU/ml IU/ml solution for perfusion intravenous use
Estonian: Trasylol Solution 10,000 KIU/ML
English: Bayer Portugal, S.A.
Estonian: Bayer d.o.o.
English: 20 mg Capsule, hard
Estonian: 20 mg Kõvakapsel
English: Implementation of the agreement by the Member States (submission of the variation by the Marketing Authorisation Holder(s) as applicable):
Estonian: Seiskoha rakendamine liikmesriikides (müügiloa hoidjad esitavad muutuste taotlused, kui asjakohane):
English: 23 October 2013
Estonian: 23. oktoober 2013
English: 19 December 2013
Estonian: 19. detsember 2013
English: Transmission to National Competent Authorities of the translations of the annexes to the agreement: 19 November 2013
Estonian: Seisukoha lisade tõlgete edastamine riiklikele pädevatele asutustele
English: What is Lipitor?
Estonian: Mis on Lipitor?
English: The European Commission issued a decision on 13 December 2010.
Estonian: Euroopa Komisjon tegi otsuse 13. detsembril 2010.
English: Lipitor is authorised in the EU via national procedures.
Estonian: Lipitor on Euroopa Liidus heaks kiidetud riiklike menetluste kaudu.
English: The maximum dose is 80 mg once a day.
Estonian: Suurim annus on 80 mg üks kord ööpäevas.
English: Adjustment of dose should be made at intervals of four weeks or more.
Estonian: Annust võib muuta nelja nädala või pikema aja tagant.
English: Why was Lipitor reviewed?
Estonian: Miks Lipitori taotlus uuesti läbi vaadati?
English: Lipitor is also available in the EU under other trade names: Atorvastatin, Atorvastatina Nostrum, Atorvastatina Parke-Davis, Atorvastatina Pharmacia, Cardyl, Edovin, Liprimar, Orbeos, Prevencor, Sortis, Tahor, Texzor, Torvast, Totalip, Xarator and Zarator.
Estonian: Lipitori turustatakse Euroopa Liidus ka teiste nimetuste all: Atorvastatin, Atorvastatina Nostrum, Atorvastatina Parke-Davis, Atorvastatina Pharmacia, Cardyl, Edovin, Liprimar, Orbeos, Prevencor, Sortis, Tahor, Texzor, Torvast, Totalip, Xarator ja Zarator.
English: The CHMP harmonised the wording for lowering blood lipids as follows:
Estonian: Inimravimite komitee ühtlustas vere lipiidisisalduse vähendamist puudutava sõnastuse järgmiselt:
English: The European Medicines Agency has completed a review of Lipitor.
Estonian: Euroopa Ravimiamet on lõpetanud Lipitori kohta tehtud taotluse läbivaatamise.
English: On 15 December 2009, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Lipitor in the EU.
Estonian: 15. detsembril 2009 tegi Euroopa Komisjon inimravimite komiteele esildise, et ühtlustada Lipitori müügiload Euroopa Liidus.
English: It must also not be used during pregnancy, while breast-feeding and in women of child-bearing potential not using appropriate contraception.
Estonian: Samuti ei tohi seda kasutada rasedad, imetavad emad ega sünnitusvõimelised naised, kes ei kasuta tõhusaid rasestumisvastaseid vahendeid.
English: The company that markets these medicines is Pfizer.
Estonian: Neid ravimeid turustab ravimifirma Pfizer.
English: The CHMP also harmonised wording for other sections of the SmPC including sections on special warnings, interaction with other medicinal products, precautions for use, pregnancy and lactation, and adverse effects.
Estonian: Komitee ühtlustas ka ravimi omaduste kokkuvõtte muud lõigud, kaasa arvatud erihoiatused, koostoime teiste ravimitega, ettevaatusabinõud kasutamisel, raseduse ja imetamise ning kõrvaltoimete lõigud.
English: The CHMP agreed that Lipitor should not be used in patients who are hypersensitive (allergic) to atorvastatin or to any of the ingredients of the medicine.
Estonian: Inimravimite komitee otsustas, et Lipitori ei tohi kasutada patsiendid, kes on atorvastatiini või ravimi mõne muu koostisaine suhtes ülitundlikud (allergilised).
English: It must not be used in patients with active liver disease or unexplained persistent elevations of serum transaminases (proteins in the blood) exceeding three times the upper limit of normal.
Estonian: Lipitori ei tohi kasutada patsiendid, kellel on aktiivne maksahaigus või ebaselgetel põhjustel seerumi transaminaaside (teatud veres leiduvad valgud) püsivalt kõrgenenud väärtused, mis ületavad referentsvahemiku ülemise piiri üle 3 korra.
English: It is also used for the prevention of a first cardiovascular event (such as a heart attack) in patients considered to be at high risk.
Estonian: Lipitori kasutatakse ka esimese kardiovaskulaarse juhu (näiteks südameataki) ennetamiseks patsientidel, kellel arvatakse olevat kardiovaskulaarse haigestumuse suur risk.
English: The CHMP agreed on the following wording for the prevention of cardiovascular events: ‘Prevention of cardiovascular events in patients estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors'.
Estonian: Kardiovaskulaarse haigestumuse ennetamise osas nõustus inimravimite komitee järgmise sõnastusega: „Kardiovaskulaarsete juhtude ennetamiseks esimese kardiovaskulaarse juhu hinnanguliselt kõrge riskiga patsientidel lisaravina muude riskitegurite kõrvaldamisel.˝
English: Lipitor is also indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.'
Estonian: Lipitor on samuti näidustatud üldkolesterooli ja LDL-kolesterooli sisalduse vähendamiseks homosügootse familiaalse hüperkolesteroleemiaga patsientidel lisaravina koos muu lipiidisisaldust vähendava raviga (nt LDL-aferees) või kui selline ravi ei ole kättesaadav.˝
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Lipitor in the European Union (EU).
Estonian: EMA inimravimite komitee järeldas, et Lipitori määramise teave tuleb Euroopa Liidus ühtlustada.
English: ‘Lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDLcholesterol (LDL-C), apolipoprotein B, and triglycerides in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.
Estonian: „Lipitor on näidustatud täiendava ravimina lisaks dieedile üldkolesterooli, LDL-kolesterooli, Bapolipoproteiini ja triglütseriidide suure sisalduse vähendamiseks primaarse hüperkolesteroleemiaga, sh familiaalse hüperkolesteroleemiaga (heterosügootne variant) või kombineeritud (sega-) hüperlipideemiaga (vastab Fredricksoni klassifikatsiooni IIa- või IIb-tüübile) patsientidel, kui dieet ega muud mittefarmakoloogilised meetodid ei ole andnud soovitud tulemust.
English: Lipitor is used together with diet to lower lipids (fats) known as cholesterol and triglycerides in the blood in patients with various types of hypercholesterolaemia (high blood cholesterol levels).
Estonian: Lipitori kasutatakse koos dieediga kolesterooli ja triglütseriidide (teatud rasvade) sisalduse vähendamiseks eri tüüpi hüperkolesteroleemiaga (vere suur kolesteroolisisaldus) patsientidel.
English: This has led to divergences across Member States in the way the medicine can be used, as seen in the differences in the summaries of product characteristics (SmPCs), labelling and package leaflets in the countries where the medicine is marketed.
Estonian: Seetõttu on ravimi näidustused, ravimi omaduste kokkuvõtted, märgistus ja pakendi infoleht Lipitori turustavates liikmesriikides erinevad.
English: Company responses provided on: 29 March 2010, 17 June 2010 Opinion date:
Estonian: 29. märts 2010, 17. juuni 2010
English: Lipitor was identified as needing harmonisation by the Co-ordination Group on the Mutual and Decentralised Procedures - Human (CMD(h)).
Estonian: Inimravimite vastastikuse tunnustamise ja detsentraliseeritud menetluse koordineerimisrühm nimetas Lipitori ühtlustamist vajavaks ravimiks.
English: Your doctor will tell you exactly how many capsules to take.
Estonian: Arst ütleb teile täpselt, kui palju kapsleid te peate võtma.
English: This medicine should be taken once a day.
Estonian: Seda ravimit tuleb võtta üks kord päevas.
English: Wait at least 1 hour until the next meal.
Estonian: Oodake vähemalt tund aega enne järgmist toidukorda.
English: Always take Advagraf exactly as your doctor has told you.
Estonian: Võtke Advagraf'i alati täpselt nii, nagu arst on teile rääkinud.
English: Advagraf with food and drink
Estonian: Advagraf' koos toidu ja joogiga
English: To date, no other relevant epidemiological data are available.
Estonian: Praeguseks puuduvad teised asjakohased epidemoloogilised andmed.
English: Date of first authorisation: 23 April 2007 Date of latest renewal: 13 April 2012
Estonian: Müügiloa esmase väljastamise kuupäev: 23.04.2007 Müügiloa viimase uuendamise kuupäev: 13.04.2012